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Abstract: The human epidermal growth factor receptor (HER) family comprises four 
homologous members: EGFR, HER-2, HER-3, and HER-4. The activation of these receptors 
triggers a complex series of signal transduction pathways which affect pivotal tumorigenic 
processes. The deregulation of HER signaling is seen in several human malignancies. HER-2 
is now recognized as a key oncogene in breast cancer pathogenesis. Assessment of HER-2 
status is of central importance in the prognosis of breast cancer patients. In the light of clinical 
data suggesting that HER-2 can also be useful as a predictive marker both for trastuzumab 
and chemotherapy, standardized determination of the HER-2 status in tumors has become 
more important. Moreover, current data provide evidence for the signiﬁ  cance of HER-3 and 
HER-4 alterations in breast carcinogenesis. Because of the complex interactions among the 
HER receptors, it is likely that the effect on cell proliferation and tumor growth depends on 
receptor trans-signaling and thus, the evaluation of the combined expression pattern of all family 
members is of particular interest. This review presents the current evidence highlighting the 
role of the family as a whole panel and an update on the role of HER-3 and HER-4 receptors 
in breast cancer. Moreover, we provide updated data regarding the prognostic value of HER 
family members giving emphasis to novel methods for the determination of their status, such 
as real-time polymerase chain reaction. In addition, we review recent therapeutic approaches 
aimed at targeting the HER family in breast cancer patients.
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Introduction
The human epidermal growth factor receptor (HER) family consists of four 
homologous members: ErbB-1 (epidermal growth factor [EGF] receptor [EGFR] 
or HER-1), ErbB-2 (HER-2) for which no ligand has been described so far, ErbB-3 
(HER-3), which is characterized by its impaired kinase activity, and ErbB-4 (HER-4). 
All family members are transmembrane glycoproteins consisting of an extracellular 
ligand-binding domain, a hydrophobic transmembrane region, and a cytoplasmic 
section containing the tyrosine kinase domain and a carboxy-terminal region with 
tyrosine autophosphorylation sites. Despite their structural homology, HER receptors 
differ in their ligand speciﬁ  cities. Two main ligand classes have been recognized so 
far: the splice variants of neuregulins (NRGs) which bind exclusively to HER-3 and/or 
HER-4 and different EGF-related proteins (Harris et al 2003). Binding of speciﬁ  c 
ligands to the extracellular domain allows for receptor homo- or heterodimerisation 
through conformational changes resulting in activation of the cytoplasmatic catalytic 
function, which leads to receptor autophosphorylation on tyrosine residues. This 
autophosphorylation triggers a complex series of signal transduction pathways such 
as phosphatidylinositol 3-kinase (PI3-K)-Akt, Ras-Raf-MEK-mitogen-activated 
protein kinase (MAPK)-dependent pathway, phospholipase C–protein kinase OncoTargets and Therapy 2008:1 6
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C (PLC–PKC), and janus kinase/signal transducer and 
activator of transcription (JAK/STAT). These pathways 
affect essential tumorigenic processes such as proliferation, 
differentiation, migration, inhibition of apoptosis, and 
enhanced survival (Mosesson and Yarden 2004; Krause and 
Van Etten 2005). Signaling diversity depends not only on the 
presence of speciﬁ  c receptors, but also on the characteristics 
of individual ligands. The HER family is characterized by 
a functional interdependency among its members, in terms 
of activity (Figure 1).
HER-2 and breast cancer
There is an extensive literature on the role of the HER family 
in breast cancer (Gullick and Srinivasan 1998) and particu-
larly that of HER-2 which is considered a key oncogene in 
breast carcinogenesis. The extracellular domain of HER-2 
is unique in that it is locked constitutively in a conforma-
tion resembling the ligand-bound states of the extracellular 
regions of the other HER receptors. As a ligand orphan 
receptor, HER-2 preferentially forms heterodimers with 
other family members. HER-2 is known to be the preferred 
heterodimerisation partner for EGFR, HER-3, and HER-4 
(Graus-Porta et al 1997) and plays an important role in trig-
gering signal transduction pathways. Moreover, heterodimers 
containing HER-2 are more mitogenic than others (Citri 
et al 2003). The transforming functions of HER-2 and its 
fundamental role in breast cancer pathogenesis are now well 
established (Moasser 2007; Ursini-Siegel et al 2007). In the 
majority of cases, HER-2 overexpression is a consequence 
of ampliﬁ  cation at the DNA level.
Overexpression or ampliﬁ  cation of HER-2 occurs in 
15% to 30% of breast carcinomas and is considered to 
confer a more aggressive biology and an unfavorable 
impact on the course of the disease (Slamon et al 1987, 
1989; Rilke et al 1991; Ross and Flether 1998). HER-2 
overexpression is associated with estrogen receptor (ER) 
and progesterone receptor (PR) negativity, high histo-
logical grade, high rates of cell proliferation and lymph 
node involvement (Rilke et al 1991; Gusterson et al 1992; 
Lebeau et al 2003). Moreover, it is correlated with disease 
aggressiveness, increased rates of recurrence and poorer 
survival in node-positive breast cancer patients, whereas 
the prognostic signiﬁ  cance in patients with node-negative 
tumors remains somewhat controversial (Borg et al 1990; 
Winstanley et al 1991; Paterson et al 1991; Clark and 
McGuire 1991; Toikkanen et al 1992; Marsigliante et al 
1993; Hartmann et al 1994; Quenel et al 1995; Mitchell 
and Press 1999).
HER-2 overexpression is also regarded as a predictive 
marker for reduced responsiveness to tamoxifen therapy 
(Tovey et al 2005; Kirkegaard et al 2007), although this is 
still an unresolved issue. The predictive value of HER-2 
expression regarding response to chemotherapy is also still 
controversial, although numerous trials have supported an 
interaction between HER-2 expression and chemotherapy 
activity (Muss et al 1994; Mass 2000; Petit et al 2001; Zhang 
et al 2003; Moliterni et al 2003). It has been suggested that 
HER-2 overexpression or ampliﬁ  cation in breast cancer 
predicts greater sensitivity to anthracycline-containing 
chemotherapy (De Placido et al 1995; Paik et al 1998, 
2000; Ravdin et al 1998; Di Leo et al 1999, 2001, 2002; De 
Laurentiis et al 2001; Moliterni et al 2003; Pritchard et al 
2006; Gennari et al 2008) and resistance to CMF regimen 
(TLBC 1988, 1989; Mansour et al 1989; Allred et al 1992; 
Gusterson et al 1992). HER-2 may also identify patients 
who are likely to beneﬁ  t from higher doses of adjuvant 
chemotherapy (Wood et al 1994; Thor et al 1998; Arnould 
et al 2003; Bonneterre et al 2003; Rodenhuis et al 2003; Del 
Mastro et al 2004; Dressler et al 2005). The association with 
response to taxane-based chemotherapy is unclear, as results 
have been conﬂ  icting (Konecny et al 2004; Gonzalez-Angulo 
et al 2004; Kostopoulos et al 2006; Hayes et al 2007).
HER-2 status determination
Assessment of HER-2 status is of crucial importance in 
the management of patients with breast cancer. In view of 
the clinical data suggesting that HER-2 can be useful as a 
predictive marker both for trastuzumab and chemotherapy, 
standardized determination of HER-2 status in tumors 
has become more important. However, while the clinical 
beneﬁ  t of assessing HER-2 status in breast carcinomas is 
now accepted, there is no consensus on the ideal diagnostic 
method to use for this purpose. HER-2 can be analyzed at the 
DNA-, the mRNA- or the protein level. Various techniques 
are available, each with beneﬁ  ts and disadvantages (Dowsett 
et al 2000).
For practical reasons, immunohistochemistry (IHC) using 
an anti-HER-2 antibody is currently the method of choice 
for HER-2 testing. IHC is a rapid, simple and convenient 
technique, readily available as a standard method in a routine 
clinical service laboratory. Moreover, IHC is a relatively 
inexpensive assay which can be easily used on archival 
formalin-ﬁ  xed parafﬁ  n-embedded (FFPE) tissues. Conse-
quently, the majority of reports published on the clinical 
signiﬁ  cance of HER-2 expression have used IHC to deter-
mine HER-2 status. However, the major drawbacks of IHC OncoTargets and Therapy 2008:1 7
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Figure 1 HER receptors and their ligands. Despite their structural homology, HER receptors differ in their ligand speciﬁ  cities. Some of these ligands bind exclusively to EGFR, 
such as EGF, TGF-α, and AREG, or bind exclusively to HER-4, such as NRG3 and NRG4. Others have a dual speciﬁ  city. So far, no ligand has been described for HER-2, whereas 
HER-3 is characterized by impaired kinase activity. HER receptors achieve activation by forming ligand-bound homo-and/or heterodimeric receptor complexes. Ten possible 
dimers can be formed (Only a few examples of dimers are presented here). HER-2 is known to be the preferred heterodimerisation partner for EGFR, HER-3 and HER-4. The 
HER-2/HER-3 heterodimer constitutes the most mitogenic dimer in the family. The HER complexes signal from the cell surface to the nucleus through numerous downstream 
pathways such as phosphatidylinositol 3-kinase (PI3-K)-Akt, Ras-Raf-MEK-MAPK-dependent pathway, PLC–PKC, and JAK/STAT. These signaling cascades eventually transmit 
their signal to TFs, which affect the transcription of target genes, regulating critical tumorigenic processes including proliferation, differentiation, apoptosis, angiogenesis, and 
migration.
Abbreviations: EGF, epidermal growth factor; TGF-α, transforming growth factor-α; HB-EGF, heparin-binding EGF-like ligand; AREG, amphiregulin; EREG, Epiregulin; BTC, 
Betacellulin; NRG, neuregulin; PI3-K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal-regulated kinase (Erk) kinase; PLC, 
phospholipase C; PKC, protein kinase C; JAK, janus kinase; STAT, signal transducer and activator of transcription; TFs, transcription factors.OncoTargets and Therapy 2008:1 8
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are that the results are not quantitative, whereas substantial 
inter-observer variations have been reported (Thomson et al 
2001). The interpretation of IHC results is subjective and 
prone to inter-observer variability, requiring experienced 
pathologists. In addition, the interpretation of the ﬁ  ndings is 
considerably inﬂ  uenced by several technical factors, such as 
the use of antibodies with variable sensitivities and speciﬁ  ci-
ties, and different ﬁ  xative protocols or staining procedures 
(Press et al 1994). While this discrepancy is improved by the 
use of standardized IHC tests (such as the HercepTest), it is 
generally recommended that (2+) HER-2 immunostaining 
requires further validation by ﬂ  uorescence in situ hybridiza-
tion (FISH) analysis (Bartlett et al 2003; Dowsett et al 2003; 
Ellis et al 2004).
FISH is a reliable, sensitive and highly speciﬁ  c technique 
for assessing HER-2 gene ampliﬁ  cation (Kjeldsen et al 2002), 
a change that appears to be correlated with strong protein 
expression (Jacobs et al 1999). In contrast to IHC, FISH can 
give a more objective and reproducible estimation of HER-2 
status. The result is quantitative, as it not only determines 
whether ampliﬁ  cation is present, but also the degree of 
ampliﬁ  cation. However, the technique is expensive and time 
consuming to perform. Moreover, FISH requires specialized 
expertise and a ﬂ  uorescence microscopy facility and thus, it 
is currently available only in a minority of pathology labo-
ratories. FISH is now being challenged by the chromogenic 
in situ hybridization (CISH) technique. CISH is similar to 
FISH, except that it uses a peroxidase reaction instead of a 
ﬂ  uorescent dye, which allows evaluation in an ordinary light 
microscope (Isola et al 2004; Laakso et al 2006).
Despite efforts to standardise these methods, considerable 
intra-laboratory and inter-laboratory variability of the results 
still exist. A number of studies indicate that approximately 
20% of HER-2 assays performed at the treatment site’s 
pathology department are incorrect when the same sample 
is reassessed in a high-volume central laboratory (Paik 
et al 2002; Roche et al 2002; Perez et al 2006). Therefore, 
improvement in reproducibility of the results between 
different laboratories is a high priority (Di Leo 2007; Wolff 
et al 2007).
Quantitative real-time reverse transcription-polymerase 
chain reaction (RT-PCR) has been recently suggested as 
an alternative technique for detection and quantiﬁ  cation 
of HER-2 status. RT-PCR produces quantitative and 
reproducible results. Moreover, it can be easily standardized, 
reduces inter-observer variability, and does not require 
experienced pathologists for interpretation. However, a 
disadvantage of this technique is the speciﬁ  c requirements 
for handling of tissue specimens to preserve the integrity of 
RNA (Masuda et al 1999).
HER-2 analyses using real-time PCR
A number of studies have used quantitative real-time PCR 
for the assessment of HER-2 status (Bieche et al 1999; 
O’Malley et al 2001; Kim et al 2002; Mrhalova et al 2003; 
Königshoff et al 2003; Ginestier et al 2004; Schlemmer et al 
2004; Suo et al 2004; Gjerdrum et al 2004; Vanden Bempt 
et al 2005; Esteva et al 2005; Benöhr et al 2005; Bossard 
et al 2005; Tse et al 2005; Vinatzer et al 2005; Kulka et al 
2006; Ntoulia et al 2006; Labuhn et al 2006). These studies 
investigated the extent of concordance of IHC, FISH 
(or CISH), quantitative PCR, and in some cases quantitative 
RT-PCR. In the majority of them, a substantial degree of 
agreement among different methods has been demonstrated, 
with respect to HER-2 status determination.
A limited number of studies have evaluated the prognostic 
power of HER-2 using quantitative real-time PCR. In a 
retrospective study, which analyzed the expression of HER-2 
by real-time RT-PCR and IHC in 131 breast carcinomas, 
HER-2 positive patients as determined by RT-PCR had worse 
outcome than the HER-2 negative group. This was evident 
in all cases as well as in the node-positive group (Potemski 
et al 2006). Vinatzer and colleagues (2005) assessed HER-2 
status at the DNA, mRNA, and protein levels with IHC, FISH 
and quantitative real-time RT-PCR in 136 tumor samples 
from 85 breast cancer patients. HER-2 overexpression, as 
determined by quantitative RT-PCR, positively correlated 
with high tumor grade, positive lymph node status, ER and 
PR negativity, consistent with published IHC results. Regard-
ing the prognostic signiﬁ  cance of HER-2 status, all methods 
showed a signiﬁ  cant correlation of HER-2 with disease-free 
survival (DFS) and overall survival (OS), except FISH alone. 
The authors concluded that quantitative RT-PCR seems to 
be clinically as useful in the assessment of HER-2 status as 
the current standard methods, yielding comparable prognostic 
information. Bergqvist and colleagues (2007) used quantita-
tive real-time PCR (Q-PCR) and RNA expression proﬁ  les 
(RNA-EPs) to evaluate HER-2 status in relation to clinical 
outcome of breast cancer patients. The authors compared 
these techniques with IHC supplemented with FISH or 
CISH. Analyses of relapse-free survival (RFS) and OS on 
the basis of 5 and 10 years of follow-up indicated equivalent 
hazard ratios for all three methods. In contrast to IHC/CISH, 
both Q-PCR and RNA-EP analyses of HER-2 also yielded 
signiﬁ  cant results regarding RFS and breast cancer-corrected 
survival after 10 years of follow-up. The results of this OncoTargets and Therapy 2008:1 9
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study suggested that both the Q-PCR and RNA-EP assays 
are associated with high-quality HER-2 status determina-
tions, and are of similar, or even superior, prognostic value 
compared with the current standard techniques.
EGFR and breast cancer
EGFR is overexpressed in several human tumors and is 
considered to initiate a variety of important steps during 
the malignant transformation (Nicholson et al 2001). In a 
review of 40 studies it was found that 45% of human breast 
carcinomas express EGFR (range 14% to 91%) (Klijn et al 
1992). In contrast to HER-2, there are no widely accepted 
criteria for the determination of EGFR status. The prognostic 
signiﬁ  cance of EGFR in breast cancer remains unclear (Chan 
et al 2006). EGFR has been correlated with ER/PR negativity 
(Fox et al 1994; Pawlowski et al 2000; Ferrero et al 2001; 
Tsutsui et al 2002; Bieche et al 2003; Bloom 2005). There 
may be an association between EGFR expression and high 
histological grade or lymph node involvement, although all 
studies are not in agreement (Fox et al 1994; Pawlowski et al 
2000; Ferrero et al 2001; Witton et al 2003; Rampaul et al 
2004, 2005; Ueda et al 2005). EGFR is generally considered 
a negative prognostic factor in breast cancer (Tsutsui et al 
2002; Witton et al 2003) but up to now, no definitive 
association between EGFR expression and survival has been 
demonstrated.
The role of EGFR in HER-2 mediated transformation 
is not fully elucidated, so far. Transformation associated 
with the human HER-2 gene has been demonstrated, 
independently of the EGFR (Chazin et al 1992). On the other 
hand, experiments have provided evidence for a synergistic 
interaction of these receptors in cellular transformation and 
induction of mammary tumors (Kokai et al 1989; Muller 
et al 1996; DiGiovanna et al 1998). Moreover, interactions 
between EGFR and HER-2 with respect to the prognosis 
of breast cancer patients have been reported. Suo et al 
suggested that EGFR expression is likely to have a synergistic 
effect on the clinical inﬂ  uence of HER-2 expression (Suo 
et al 2002). In another study, Di Giovanna and colleagues 
(2005) showed that breast cancer patients whose tumors 
demonstrated co-overexpression of EGFR and HER-2 had 
the shortest survival.
HER-3 and breast cancer
The HER-3 gene is located on chromosome 12q13 and 
the encoded protein receptor binds to NRG isoforms. 
HER-3 overexpression has been documented in 20% to 
30% of invasive breast carcinomas (Karamouzis et al 2007). 
Moreover, HER-3 is frequently co-expressed with HER-2 
(Naidu et al 1998; Bieche et al 2003; Witton et al 2003; 
Sassen et al 2008), suggesting a role of this receptor in 
HER-2 mediated carcinogenesis. HER-3 signaling relies 
on the formation of signaling-competent heterodimers with 
other members of the HER family. Ligand-bound or even 
ligand-independent HER-3 may form signaling complexes 
with HER-2. It has been demonstrated that the HER-2/
HER-3 heterodimer constitutes the most mitogenic dimer 
in the HER family (Citri et al 2003). It seems that these two 
receptors cooperate synergistically in neoplastic transfor-
mation (Alimandi et al 1995). This hypothesis is supported 
by Holbro and colleagues (2003) who showed that HER-3 
couples active HER-2 to the downstream signaling PI3-K/
protein kinase B pathway. In another study, the activity of 
HER-3 decreased dramatically when the HER-2 receptor was 
blocked, suggesting that HER-2/HER-3 dimers are necessary 
for sustained signaling (Neve et al 2000). Liu and colleagues 
(2007) indicated that downregulation of HER-3 inhibits 
HER-2 mediated procarcinogenic activity via inactivation of 
the PI3-K/Akt pathway. Furthermore, HER-3 also contributes 
to HER-2 associated tamoxifen resistance. HER-2/HER-3 
heterodimers signal through the PI3-K/Akt pathway, which is 
known to be activated in a wide range of cancers. HER-2 does 
not directly bind PI3-K and this function is mediated through 
HER-3, which has multiple tyrosine containing binding 
sites for p85, the regulatory subunit of PI3-K (Prigent and 
Gullick 1994; Soltoff et al 1994). On the other hand, it has 
been demonstrated that a naturally occurring secreted form 
of the human HER-3 receptor, p85-soluble ErbB3 (sErbB3), 
is a potent negative regulator of heregulin-stimulated HER-2, 
HER-3 and HER-4 activation (Lee et al 2001).
The prognostic value of HER-3 expression in breast 
cancer is poorly documented and the available data are still 
controversial (Lemoine et al 1992; Gasparini et al 1994; 
Quinn et al 1994; Travis et al 1996; Pawlowski et al 2000; 
Karamouzis et al 2007). Although overexpression of HER-3 
has been linked to HER-2 positivity (Gasparini et al 1994) 
and lymph node involvement (Lemoine et al 1992; Bieche 
et al 2003), a deﬁ  nitive relationship with survival has not 
been established. In a study which evaluated HER family by 
IHC, patients with tumors that stained HER-3 strongly had 
signiﬁ  cantly reduced survival (Witton et al 2003), whereas 
in a recently reported study, a negative impact of HER-3 
gene ampliﬁ  cation on DFS was demonstrated (Sassen et al 
2008). In contrast, other studies have suggested a positive 
prognostic value of HER-3 receptor status. Quinn and 
colleagues (1994) showed that HER-3 overexpression was OncoTargets and Therapy 2008:1 10
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positively, but not signiﬁ  cantly, related to negative lymph 
node status and survival, whereas Knowlden and colleagues 
(1998) have demonstrated that increased HER-3 mRNA 
appears to be associated with the prognostically favorable 
ER phenotype. Moreover, Pawlowski and colleagues (2000) 
reported a univariate positive impact of HER-3 mRNA on 
survival. In a recent study, Lee and colleagues (2007) found 
that expression of HER-3 was correlated with positive ER 
and PR status and inversely correlated with histological 
grade. In the same study, HER-3 expression was associated 
with longer DFS.
HER-4 and breast cancer
The HER-4 gene is located on chromosome 2q33.3–34 and 
the encoded protein can be activated by both NRGs and 
some ligands of the EGF family. In contrast to the other 
HER receptors, the existing evidence suggests that HER-4 is 
characterized by antiproliferative activity (Sartor et al 2001; 
Naresh et al 2006). Moreover, HER-4 overexpression has 
been reported as a favorable prognostic factor in the literature. 
This positive effect is most likely associated with growth 
controling and differentiation signaling. HER-4 is expressed 
in four isoforms, one of which, ErbB4 CYT-2, lacks a 
PI3-K binding site and thus is incapable of activating PI3-K 
signaling pathway (Kainulainen et al 2000). Other studies 
have indicated that NRG-activated HER-4 homodimers 
stimulate only the apoptosis-controling PI3-K/Akt pathway 
and not cell proliferation (Yarden and Sliwkowski 2001). In 
cell line experiments, when HER-2 positive cancer cells were 
transfected to overexpress HER-4, a reduction in proliferation 
and an increase in apoptosis were observed (Sartor et al 
2001), suggesting that HER-4 antagonizes HER-2 signaling 
activity (Barnes et al 2005). More recent studies have 
increased our knowledge regarding the HER-4 associated 
apoptosis (Naresh et al 2006). On the other hand, contrasting 
results of the prognostic signiﬁ  cance of HER-4 have also 
been reported (Bieche et al 2003). Tang and colleagues 
(1999) have shown that ribozyme-mediated down-regulation 
of HER-4 in breast cancer cells inhibits their proliferation 
both in vitro and in vivo. These differences may be explained 
by the variable responses of HER-4 to its ligands, resulting in 
either proliferation or differentiation, and perhaps inﬂ  uenced 
by dimerisation with other HER-family members.
HER-4 expression has been associated with favorable 
prognostic factors (ER positivity, low histological grade) 
(Knowlden et al 1998; Tang et al 1999; Kew et al 2000; 
Suo et al 2002; Witton et al 2003; Zaczek et al 2008) 
and a more favorable outcome in breast cancer patients 
(Pawlowski et al 2000; Suo et al 2002; Witton et al 2003; 
Aubele et al 2007). Suo et al (Suo et al 2002) suggested 
that HER-4 antagonizes the HER-2 effect on the patient 
clinical course and thus, integrating HER-4 status analysis 
into the diagnosis of breast cancer may also be of importance 
(Barnes et al 2005). In contrast, Bieche and colleagues 
(2003) suggested that HER-4 mRNA status might be a 
molecular marker of poor outcome in subsets of breast 
cancer patients.
Studies evaluating the HER family 
as a whole panel
Most clinicopathological studies have focused on the 
expression and/or gene ampliﬁ  cation of individual HER 
family members. Consequently, the clinical outcome of 
breast cancer patients with regard to HER family as a whole 
panel remains largely unidentiﬁ  ed. Because of the complex 
interactions among the HER receptors, it is likely that the 
effect on cell proliferation and tumor growth depends on 
receptor trans-signaling and thus, the evaluation of the 
combined expression pattern of all family members is of 
particular interest.
Few data are available on the expression pattern of 
all four HER receptors in large series of breast tumors. In 
a study (Witton et al 2003) which investigated the HER 
family by IHC in 220 breast carcinomas, patients whose 
tumors overexpressed EGFR, HER-2, or HER-3 had 
reduced survival (P  0.001), whereas those whose tumors 
overexpressed HER-4 had increased survival (P = 0.013). 
In Cox’s multiple regression analysis, EGFR, HER-2, HER-3 
and HER-4 positivity, independently affected the survival. 
A recent study (Sassen et al 2008) evaluated the four 
members (EGFR, HER-2, HER-3, HER-4), both at the DNA 
and protein levels using FISH and IHC, in 278 patients. In 
this study, the negative impact of HER-2 ampliﬁ  cation on 
patient DFS and OS was veriﬁ  ed. Moreover, a univariate 
negative impact of HER-3 gene ampliﬁ  cation on DFS was 
demonstrated (P = 0.031).
A number of studies have demonstrated strong correla-
tions between HER mRNA copy numbers and HER protein 
levels, suggesting that HER family expression can reliably be 
assessed at the mRNA level (Knowlden et al 1998; Srinivasan 
et al 1998; Walker and Dearing 1999; Suo et al 2002). Data 
regarding the evaluation of all HER family members using 
RT-PCR are limited. Suo et al evaluated the HER family 
members using IHC and RT-PCR in 100 breast cancer patients. 
In this study, all the immunoreactive tumors were conﬁ  rmed 
positive by RT-PCR. Statistical analysis revealed a signiﬁ  cant OncoTargets and Therapy 2008:1 11
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association between HER-2 expression and reduced DFS 
(P = 0.033) and cancer-speciﬁ  c survival (P = 0.042). HER-4 
expression was correlated with a longer DFS (P = 0.049) and 
cancer-speciﬁ  c survival (P = 0.044). Co-expression of HER-2 
and EGFR was associated with a worse prognosis (Suo et al 
2002). Pawlowski and colleagues (2000) assessed the 
expression of the family with real-time RT-PCR, in a series 
of 365 breast cancers. HER-3 and HER-4 were positively 
correlated to each other and negatively correlated to EGFR. 
In RFS studies, Cox univariate analyses revealed prognostic 
value of HER-4 (P = 0.015; risk ratio [RR], 0.65) which 
was retained in multivariate analyses (P = 0.035; RR, 0.67). 
Regarding OS studies, univariate analyses demonstrated 
prognostic signiﬁ  cance of EGFR (P = 0.026; RR, 1.6), HER-3 
(P = 0.0093; RR, 0.58), and HER-4 (P = 0.0024; RR, 0.52), 
whereas the expression of HER-2 was not a prognostic 
factor. In the multivariate analyses, none of these receptors 
maintained their prognostic value on OS. HER-4 was found 
to be an independent prognostic factor on RFS (Pawlowski 
et al 2000). Bieche and colleagues (2003) used a real-time 
quantitative RT-PCR assay to quantify HER family mRNA 
copy numbers in 130 breast tumors from patients with 
known long-term outcome. In this study, a positive correla-
tion between HER-3 and HER-4 mRNA levels was found, 
together with a negative correlation between the expression 
of these two genes and that of EGFR. RFS was shorter among 
patients with HER-3-overexpressing tumors (P = 0.0092) 
and longer among those with HER-4-underexpressing 
tumors (P = 0.0085), relative to patients with normal 
expression of the respective genes. In contrast, RFS was not 
signiﬁ  cantly inﬂ  uenced by EGFR or HER-2 mRNA status. 
Only HER-4 retained its prognostic signiﬁ  cance in Cox 
multivariate regression analysis (P = 0.015).
The existing data with respect to the expression of HER 
family members, particularly that of EGFR, HER-3, and 
HER-4, are extremely variable and thus, a comparison of the 
results from different studies is difﬁ  cult. Most of those studies 
have evaluated the expression at the protein level, whereas 
the majority of them have not investigated the expression 
of all HER members simultaneously. Up to now, it is not 
clear whether the assessment of the prognostic value of the 
HER family at the DNA-, the mRNA- or the protein level 
yields comparable results. In a study which investigated the 
HER receptors using both IHC and RT-PCR, the authors 
used protein expression for the evaluation of relationships 
to clinicopathological parameters, considering that the bio-
logical inﬂ  uence of these factors is reﬂ  ected by protein level 
(Suo et al 2002). Studies evaluating the HER receptors as 
a whole panel at the protein level have conﬁ  rmed the value 
of HER-2 as a negative prognostic factor (Suo et al 2002; 
Witton et al 2003; Sassen et al 2008). A similar ﬁ  nding was 
not demonstrated in studies which assessed the HER family 
at the mRNA level (Pawlowski et al 2000; Bieche et al 
2003), although those which investigated the prognostic 
power of HER-2 only, using real-time RT-PCR, showed that 
this technique seems to be as useful as the current standard 
methods, yielding comparable correlations of HER-2 status 
with the patient outcome (Vinatzer et al 2005; Potemski et al 
2006; Bergqvist et al 2007). Regarding the EGFR receptor, 
although a number of studies suggest a negative prognostic 
value (Pawlowski et al 2000; Witton et al 2003), others have 
failed to demonstrate its prognostic signiﬁ  cance (Bieche et al 
2003; Sassen et al 2008). Furthermore, most of the studies 
evaluating the HER family are in agreement regarding 
the negative prognostic value of HER-3 in breast cancer 
patients (Bieche et al 2003; Witton et al 2003; Sassen et al 
2008). Likewise, the favorable impact of HER-4 on patient 
outcome has been demonstrated through the majority of the 
studies which assessed all family members simultaneously 
(Pawlowski et al 2000; Suo et al 2002; Witton et al 2003). 
Moreover, co-expression of HER receptors (EGFR/HER-2, 
HER-2/HER-3, HER-2/HER-4) is likely to have clinical 
importance, due to the possible synergistic or antagonistic 
effect among HER family members.
The results of studies evaluating the HER family 
demonstrate a complex expression pattern of HER receptors 
in breast cancer patients. Moreover, the available data 
provide evidence of an implication of HER-3 and HER-4 
alterations in breast carcinogenesis. Thus, it is likely that 
HER-3 and HER-4 could have a role as prognostic markers 
and that their integration into the routine management of 
the disease would provide useful additional information. 
Taken together, the ﬁ  ndings of the relevant studies indicate 
that the combined expression proﬁ  le of the HER family, and 
not the isolated expression of individual members, is likely 
to be more important when assessing the prognosis of the 
patients. Therefore, it is possible that studies evaluating the 
HER receptors as a whole panel may shed light on the role 
of the HER family in breast carcinogenesis and open new 
directions in patient management.
Targeting the HER family
Based on the evidence implicating the HER family in breast 
cancer pathogenesis, numerous approaches aimed at targeting 
these receptors have been developed (Petrelli et al 2008). 
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on HER-2 activity has rendered this receptor an attractive 
target. A humanized monoclonal antibody directed against the 
HER-2 protein, trastuzumab (Herceptin), has demonstrated 
substantial efﬁ  cacy in breast cancer and has been consid-
ered as a “therapeutic revolution” in the management of the 
disease. Clinical trials evaluating trastuzumab monotherapy 
in HER-2 positive metastatic breast cancer have indicated 
overall response rates ranging from 15% to 30% (Vogel et al 
2002; Baselga et al 2005a). The pivotal phase III study showed 
that the addition of trastuzumab to ﬁ  rst-line chemotherapy 
[either doxorubicin (or epirubicin) and cyclophosphamide 
or paclitaxel] was associated with a longer survival (median 
survival, 25.1 vs 20.3 months; P = 0.01) in patients with 
metastatic breast cancer and HER-2 overexpression (Slamon 
et al 2001). Furthermore, a recent phase II randomized trial 
which compared ﬁ  rst-line trastuzumab plus docetaxel versus 
docetaxel alone in patients with HER-2 positive metastatic 
breast cancer, showed a survival advantage (median survival, 
31.2 vs 22.7 months; P = 0.0325) from the addition of 
trastuzumab to chemotherapy (Marty et al 2005). Various 
nonrandomized studies have demonstrated the activity of 
trastuzumab in combination with the majority of chemothera-
peutic agents used in the management of breast cancer.
The efﬁ  cacy of trastuzumab in patients with advanced 
disease prompted the evaluation of this monoclonal antibody 
in patients with HER-2 positive early breast cancer. Four 
randomized trials have been recently reported, showing that 
the addition of trastuzumab to adjuvant chemotherapy halves 
the risk of relapse (Romond et al 2005; Piccart-Gebhart et al 
2005; Slamon et al 2005; Joensuu et al 2006). Moreover, in 
the joint analysis of two North-American trials, treatment 
with trastuzumab for 52 weeks, combined with paclitaxel 
after doxorubicin and cyclophosphamide, was associated 
with a 33 percent reduction in the risk of death (P = 0.015) 
among women with surgically removed HER-2 positive 
breast cancer (Romond et al 2005). Likewise, after a median 
follow-up of 2 years in the Herceptin Adjuvant (HERA) study 
which compared 1 or 2 years of trastuzumab treatment with 
observation alone after standard neoadjuvant or adjuvant 
chemotherapy, 1 year of treatment with trastuzumab was 
associated with a signiﬁ  cant reduction in the risk of death 
(P = 0.0115) (Smith et al 2007). However, only interim 
analyses with relatively short follow-up have been reported so 
far and thus, important issues with respect to the cumulative 
toxicity and the optimal duration of use of trastuzumab in the 
adjuvant treatment of early breast cancer remain unclear.
The mechanisms of trastuzumab action have not been fully 
elucidated yet (Valabrega et al 2007). Accumulating data 
indicate that the effect of trastuzumab on cancer cells may 
be due to the activation of antibody-dependent cellular 
cytotoxicity (ADCC) (Lewis et al 1993; Cooley et al 1999; 
Clynes et al 2000; Gennari et al 2004). Other possible 
mechanisms of action include inhibition of shedding of the 
extracellular HER-2 domain (Molina et al 2001), induction 
of HER-2 downregulation and degradation (Austin et al 
2004; Valabrega et al 2005), inhibition of the PI3-K pathway 
(Delord et al 2005), inhibition of angiogenesis (Izumi 
et al 2002; Klos et al 2003) and G1 cell cycle arrest (Lane 
et al 2001).
Resistance to trastuzumab treatment may be either 
primary or secondary. It has been shown that only 15% to 
30% of HER-2 overexpressing metastatic breast cancers 
responded to trastuzumab monotherapy (Vogel et al 2002; 
Baselga et al 2005a). In the majority of these cases the 
disease will progress, usually within one year (Slamon et al 
2001). Even in the adjuvant setting, approximately 15% of 
patients eventually develop metastatic disease. Thus, both 
de novo and acquired resistance are signiﬁ  cant problems 
in patients treated with trastuzumab (Bender and Nahta 
2008). Although the development of resistance remains 
unclear, several hypotheses have been suggested. These 
include loss of the tumor-suppressor phosphatase with 
tensin homologue (PTEN) (Nagata et al 2004), activation of 
alternative signaling pathways such as insulin-like growth 
factor-I receptor (IGF-IR) pathway (Lu et al 2001), increased 
expression of ligands of the HER family receptors such as 
transforming growth factor-α (TGF-α) (Valabrega et al 
2005) and receptor masking or epitope inaccessibility (Nagy 
et al 2005).
Another potential mechanism of resistance is the presence 
of multiple truncated forms of HER-2 and the effects of 
these forms on trastuzumab response (Nahta and Esteva 
2007). HER-2 targeted monoclonal antibodies have been 
shown to bind to circulating HER-2 ECD, decreasing the 
level of antibodies available to bind to membrane-bound 
HER-2 (Zabrecky et al 1991). Moreover, the accumulation 
of truncated forms of the HER-2 receptor that lack the 
extracellular trastuzumab-binding domain represents another 
possible mechanism of resistance. Amino terminally trun-
cated carboxyl terminal fragments of HER-2, collectively 
known as p95HER2 or C-terminal fragments, are frequently 
found in HER-2 overexpressing breast cancer cell lines and 
tumors (Molina et al 2002). These fragments result either 
from alternative translation start sites (Anido et al 2006) 
or through the proteolytic shedding of the extracellular 
domain of HER-2 (Christianson et al 1998). In a recent study OncoTargets and Therapy 2008:1 13
EGFR in breast cancer
(Scaltriti et al 2007), breast cancer cells stably expressing 
p95HER2 were resistant to trastuzumab but remained 
sensitive to the antiproliferative effects of the tyrosine kinase 
inhibitor (TKI) lapatinib, both in vitro and in vivo. Further-
more, in a series of patients with HER-2 positive metastatic 
breast cancer treated with trastuzumab, the presence of 
p95HER2 was correlated with clinical resistance, whereas 
tumors expressing only the full-length receptor exhibited a 
high response rate (Scaltriti et al 2007).
Trastuzumab engages both activatory (fragment 
C receptor [Fc gamma R] IIIa; Fc gamma RIIa) and 
inhibitory (Fc gamma RIIb) antibody receptors. Fc gamma 
R polymorphisms may affect the ADCC of natural-killer 
cells/monocytes. Recently, Musolino and colleagues (2008) 
evaluated the role of Fc gamma RIIIa, Fc gamma RIIa, and 
Fc gamma RIIb polymorphisms in predicting activity of 
trastuzumab in patients with HER-2 positive metastatic breast 
cancer. In this study, the Fc gamma RIIIa 158 valine/valine 
(V/V) genotype, alone and in combination with the Fc gamma 
RIIa 131 histidine/histidine (H/H) genotype, was signiﬁ  cantly 
associated with better response rate and progression-free 
survival to trastuzumab compared with other Fc gamma 
R genotypes. Moreover, ADCC analysis showed that 
158 V/V and/or 131 H/H peripheral blood mononuclear cells 
(PBMCs) had a signiﬁ  cantly higher trastuzumab-mediated 
cytotoxicity than PBMCs harboring other genotypes. This 
study supports the hypothesis that Fc gamma R polymor-
phisms play a role in trastuzumab-mediated ADCC and have 
predictive ability in patients with breast cancer treated with 
trastuzumab-based therapy.
Since a considerable proportion of patients do not respond 
to trastuzumab, the evaluation of additional molecular 
parameters such as alternate HER family members or the 
co-expression profile of HER receptors, is an ongoing 
challenge. Cetuximab is a chimeric monoclonal antibody that 
competitively binds to the extracellular domain of the EGFR. 
A randomized phase II study evaluated the combination of 
weekly irinotecan/carboplatin with or without cetuximab 
in patients with metastatic breast cancer (O’Shaughnessy 
et al 2007). The preliminary assessment showed that the 
addition of cetuximab to chemotherapy was associated 
with a higher response rate but also with greater toxicity. 
Clinical studies evaluating EGFR TKIs failed to demon-
strate activity in metastatic cancer patients with disease 
refractory to chemotherapy (Roy and Perez 2006). Available 
data from phase II trials which investigated the EGFR TKI 
geﬁ  tinib in pretreated patients have shown limited efﬁ  cacy 
(Albain et al 2002; Baselga et al 2005b; von Minckwitz 
et al 2005). Furthermore, when geﬁ  tinib was combined 
with ﬁ  rst-line chemotherapy, an additional beneﬁ  t was not 
found (Fountzilas et al 2005). A combination of erlotinib 
with docetaxel as ﬁ  rst-line treatment resulted in a response 
rate of 55% (Kaur et al 2006). However, the nonrandomized 
nature of this trial does not clarify the added beneﬁ  t with 
respect to the efﬁ  cacy of erlotinib. A number of studies have 
demonstrated underexpression of the EGFR receptor in breast 
tumors (Dittadi et al 1993; Robertson et al 1996; DeFazio 
et al 2000; Bieche et al 2003). Moreover, in another study 
a marked reduction of EGFR expression with breast cancer 
progression was found, and such a decrease of expression of 
the receptor was associated with resistance to geﬁ  tinib in vitro 
(Choong et al 2007). These ﬁ  ndings might be an explanation 
for the low activity of EGFR TKIs in breast cancer and are 
likely to have implications in the design of further clinical 
trials targeting the HER family.
It has been suggested that the form of EGFR/HER-2 
dimers might be important for breast cancer cell growth and 
thus, the inhibition of these receptors could possibly block 
cell proliferation (Jannot et al 1996). Recently, it has been 
found that the growth inhibitory activity of trastuzumab on 
HER-2 overexpressing breast cancer cells is signiﬁ  cantly 
modulated by EGFR co-expression (Diermeier et al 2005). 
Therefore, it is likely that the optimization of treatments 
targeting the HER family requires to account for EGFR 
co-expression. Lapatinib is an oral dual TKI selective for 
inhibition of EGFR and HER-2. It shows synergy with trastu-
zumab, and has demonstrated clinical activity in trastuzumab-
resistant tumors (Blackwell et al 2004). Recent data provide 
encouraging evidence of the effectiveness of lapatinib in 
advanced breast cancer and for its potential in patients 
with brain metastases (Gomez et al 2005; Geyer et al 2006; 
Cameron et al 2008). Several clinical studies exploring the 
activity of lapatinib in combination with chemotherapeutic 
agents, hormonal therapy and other targeted treatments are 
ongoing in advanced or in neo-adjuvant and adjuvant settings 
(Bilancia et al 2007). In contrast, dual targeting of EGFR 
and HER-2 using concomitant geﬁ  tinib and trastuzumab 
might be detrimental in breast cancer patients, due to a 
possible antagonistic effect between these agents (ECOG 
E1100 2003).
The relatively limited activity of TKIs in HER-2 
overexpressing breast tumors is likely to be associated 
with a failure to inhibit HER-3 efﬁ  ciently. Even though 
these agents block EGFR and HER-2 autophosphoryla-
tion, the transphosphorylation of HER-3 is only tran-
siently inhibited, leading to PI3-K/Akt pathway resistance OncoTargets and Therapy 2008:1 14
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(Sergina et al 2007). Therefore, the HER-3 receptor might 
also present a challenging target that could potentially over-
come TKI resistance. However, the inhibition of HER-3 
using current therapeutic approaches would be difﬁ  cult since 
this receptor is catalytic kinase deﬁ  cient and thus, not a 
direct target of TKIs (Hsieh and Moasser 2007). Moreover, 
another therapeutic approach is to inhibit simultaneously all 
members of the HER family using TKIs such as canertinib. 
Nevertheless, a number of studies have indicated that HER-4 
antagonizes the effect of HER-2 on the clinical course of 
breast cancer (Suo et al 2002) and thus, the use of pan-HER 
targeted treatments could possibly attenuate the favorable 
effect of HER-4 on patient outcome.
Accumulating data suggest that ER and HER-2 have a 
bidirectional cross talk which leads to tamoxifen resistance 
or conversion of tamoxifen to an ER agonist (Pietras 
et al 1995; Shou et al 2004; Yang et al 2004). Increased 
expression of EGFR and HER-2 receptors might be 
associated with tamoxifen resistance (Schiff et al 2005; 
Massarweh et al 2008). In a recent study (Kirkegaard et al 
2007), high ampliﬁ  ed in breast cancer 1 (AIB1) expression 
in patients with HER-2 and HER-3 overexpressing tumors 
or tumors expressing one or more of EGFR, HER-2, or 
HER-3 was associated with an increased risk of relapse on 
tamoxifen. These ﬁ  ndings indicate a cross-talk between 
ER-alpha and growth factor receptor pathways through 
changes in expression of speciﬁ  c coactivator proteins, such 
as AIB1. A number of studies have investigated the use of 
drugs against EGFR, in tamoxifen-resistant breast cancer 
(Nicholson et al 2002; Knowlden et al 2003; Nicholson et al 
2004). Moreover, clinical trials have examined the inhibi-
tion of growth factor signaling as a therapeutic strategy in 
endocrine-resistant breast cancer patients (Robertson et al 
2003; Marcom et al 2007).
In conclusion, the HER family represents an attractive 
area for the application of targeted therapies in breast cancer 
and considerable treatment advances have been made so far. 
However, the incorporation of targeted agents into the treat-
ment of the disease has been associated with variable and in 
some cases unexpected results. HER-2 overexpression alone 
is probably inadequate to predict the impact of targeted agents 
on cell proliferation. Since trans-signaling is now considered 
an essential feature of HER family function, the role of lateral 
signaling partners such as HER-3 is increasingly recognized. 
Studies including a more comprehensive evaluation of all 
HER receptors and their ligands are required to elucidate 
how these different signaling pathways interact in breast 
carcinogenesis, providing a basis for the development of 
targeted treatments with respect to individualized patient 
management.
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